Biogen finally culls MS dud opicinumab, adds SMA gene therapy to the garbage heap

Biogen finally culls MS dud opicinumab, adds SMA gene therapy to the garbage heap

Source: 
Fierce Biotech
snippet: 

Biogen is cutting its experimental multiple sclerosis (MS) drug opicinumab as well as an spinal muscular atrophy (SMA) candidate amid a third-quarter clear-out.

First, to its MS drug. In its third-quarter financials posted Wednesday morning, the biopharma said: “In October 2020 Biogen announced that the phase 2 AFFINITY study of opicinumab in MS did not meet its primary or secondary endpoints and that Biogen has discontinued development of opicinumab.”